Exicure Inc.
01/22/2026 | Press release | Distributed by Public on 01/22/2026 15:29
Material Event (Form 8-K)
Item 8.01 Other Events
Completion of Milestone 1
On January 16, 2026, Exicure, Inc. (the "Company") achieved the first contractual milestone under its License and Collaboration Agreement (the "Agreement") with GPCR Therapeutics Inc. The milestone relates to the completion of the Company's Phase 2 clinical trial of its novel stem cell mobilizer (NCT05561751), which was achieved through the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. Under the terms of the Agreement, the Company is required to make a milestone payment of $1,000,000 to GPCR Therapeutics Inc. within 30 days of achieving this milestone. The Company intends to make this payment in accordance with the terms of the Agreement.
The Company believes that achieving this milestone reflects continued progress in the development and advancement of the small molecule CXCR4 inhibitor, Burixafor (GPC-100). In addition, under the terms of the Agreement, completion of this milestone triggers the future sublicensing income-sharing ratio, reflecting the Company's increased participation in and commitment to the long-term success of the program.
Exicure Inc. published this content on January 22, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 22, 2026 at 21:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]